Mounjaro is an incretin injection Tirzepatide developed by Eli Lilly (trade name Mounjaro, Chinese trade name 猛健樂). It has been approved by the U.S. FDA for use in patients with type 2 diabetes and has also obtained indication for weight loss in Europe and the United States. In Taiwan, the Ministry of Health and Welfare Food and Drug Administration (TFDA) has approved its indication as an adjunct treatment to diet and exercise for improving blood glucose control in adult patients with type 2 diabetes.
Mounjaro is similar to Ozempic, requiring only once-weekly injections, and is currently the world’s first dual incretin GLP-1 and GIP receptor agonist. By combining the actions of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), it efficiently regulates energy metabolism, improves blood glucose and lipid levels, provides cardiovascular health benefits, enhances satiety, and reduces overeating.
